Virtual CME Program
1.00 CME/CE Credit
The Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Closer Look at the 2022 ACC Expert Consensus Decision Pathway
This program is designed to improve health care providers' knowledge and competence about available lipid-lowering medications and how to use these agents to narrow the treatment gap and improve outcomes in patients with heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD).
CME/CE Information
1.00 AMA PRA Category 1 Credits, 1.00 ABIM MOC or 1.00 AANP, including 0.75 AANP Pharm
Release Date: 8/9/2023
Expiration Date: 8/9/2024
Topics
Learning Objectives
- Identify factors that lead to poor statin adherence and relevant management strategies
- Summarize data supporting residual ASCVD risk in statin patients unable to reach LDL-C goals
- Apply the clinical trial data and guidelines for the use of nonstatin treatments in patients with ASCVD and HeFH
- Consider clinical characteristics and preferences in order to select the most appropriate non-statin therapies in the management of patients with residual hypercholesterolemia
Faculty
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC
Associate Director of Preventive Cardiology
Division of Cardiology,
Johns Hopkins School of Medicine
(Baltimore, MD)
Co-Editor-in-Chief, American Journal
of Preventive Cardiology
Kevin Maki, PhD, CLS, FNLA, FTOS, FACN
President & Chief Scientist, Midwest Biomedical Research (Addison, IL)
Adjunct Professor, Dean’s Eminent Scholar,
Indiana University School of Public Health (Bloomington, IN)
Co-Editor-in-Chief, Journal of Clinical Lipidology
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Kevin C. Maki, PhD, CLS: Consultant and Independent Contractor for Beren Therapeutics; Consultant and Independent Contractor for New Amsterdam Pharma.
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC: Advisor for Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk, and Pfizer.
Peter Libby, MD: Consultant for Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Moderna, Novo Nordisk, Novartis, Pfizer, and Sanofi-Regeneron. Advisor for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Eulicid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, and PlaqueTec. Researcher for Novartis, Novo Nordisk and Genentech
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
CME/CE Information
AMA PRA Category 1 Credits
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Iridium Continuing Education. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Iridium Continuing Education. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.
Designation Statement
This activity is approved for 1.00 contact hour of continuing education, which includes 1.00 hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Obtaining Credit
Supporters and Partners
Commercial Supporter
Novartis Pharmaceutical Corporation and
Esperion Therapeutics, Inc.
Education Partner
Iridium Continuing Education, LLC
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.